Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hodgkin Lymphoma: early-phase trial registry
28 of 72 indexed Hodgkin Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #191 of 28,707 conditions by registered trial count.
72 US clinical trials · 28 currently recruiting · #191 of 28,707 conditions by registered trial count
Hodgkin Lymphoma: 72 US clinical trials tracked, 28 recruiting.
Hodgkin Lymphoma is the subject of 72 registered US clinical trials on ClinicalTrials.gov, 28 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 58 in Phase 1-2 (earlier-stage). The most active sponsor is St. Jude Children's Research Hospital, running 7 of these trials.
Enrollment posture brief
Registry condition hodgkin-lymphoma
OPEN 28 | RECR 39% | LATE 1 | EARLY 58 | RANK #191 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Chronic Myeloid Leukemia (39% recruiting · 36 trials)
Hodgkin Lymphoma lists 28 open slots (39% of 72 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hodgkin Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hodgkin Lymphoma recruits in line with its size-band peers.
28 of 72 indexed trials (38.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hodgkin Lymphoma trials is spread across many organizations.
St. Jude Children's Research Hospital accounts for 7 of 72 trials (9.7%). 46 distinct sponsors appear on at least one study for this condition label.
-
Most Hodgkin Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 72 trials that report a genuine target (sentinel values excluded). 52 of those (72.2%) plan for fewer than 100 participants.
-
Hodgkin Lymphoma research is mostly interventional.
67 interventional and 5 observational studies make up this index (93.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
72 total, page 2 of 2
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
NCT03179917
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Masonic Cancer Center, University of Minnesota
NCT03674411
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
Catherine Bollard
NCT03843294
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
M.D. Anderson Cancer Center
NCT03622788
Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL
Dana-Farber Cancer Institute
NCT04938232
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
Stanford University
NCT04788043
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
NCT04060277
Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
National Cancer Institute (NCI)
NCT00339963
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Bristol-Myers Squibb
NCT01592370
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
Merck Sharp & Dohme
NCT05508867
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
Dana-Farber Cancer Institute
NCT02362997
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
Jennifer Amengual
NCT01947140
Brentuximab for Newly Diagnosed Hodgkin Disease
Mitchell Cairo
NCT02398240
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT
University of Virginia
NCT04629430
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Massachusetts General Hospital
NCT02505269
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
National Cancer Institute (NCI)
NCT00013533
A Study to Assess AFM13 in Patients With Hodgkin Lymphoma
Affimed
NCT01221571
Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Xencor
NCT00606645
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Stanford University
NCT03734601
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Robert Lowsky
NCT02424968
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
H. Lee Moffitt Cancer Center and Research Institute
NCT05065866
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
NCT02129582
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 26 |
| Phase 2 | 32 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hodgkin Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hodgkin Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hodgkin Lymphoma page
72 registered trials, 28 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 28 Hodgkin Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- St. Jude Children's Research Hospital sponsors the most Hodgkin Lymphoma trials on record, review their full trial history before evaluating a specific study. See St. Jude Children's Research Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hodgkin Lymphoma condition card totals 72 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.